Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 422-436

  du Bois, Andreas ^a   Rochon, Justine ^b   Pfisterer, Jacobus ^c   Hoskins, William J ^d  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Centralization; Gynecologic oncology; Outcome; Ovarian cancer; Specialization; Volume

Indexed keywords

CANCER SURVIVAL; CERTIFICATION; EXPERIENCE; HUMAN; MEDICAL EDUCATION; MEDICAL SPECIALIST; MEDLINE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW;

FEMALE; GYNECOLOGY; HOSPITALS; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; OVARIAN NEOPLASMS; SPECIALTIES, MEDICAL;

EID: 58249106854     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.036     Document Type: Review

References (88)

1. In: Parkin D.M., Whelan S.L., Ferlay J., Teppo L., and Thomas D.B. (Eds). Cancer incidence in five continents Vol. VIII (2002), IARC Scientific Publications No. 155, Lyon, France
2. Heintz A.P.M., Odincino F., Maisonneuve P., et al. Carcinoma of the ovary. In: Pecorelli S. (Ed). FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiology Biostatistics 6 (2001) 107-138
3. Berrino F., Capocaccia R., Coleman M.P., et al. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann. Oncol. 14 Suppl 3 (2003) v100
4. Grilli R., Minozzi S., Tinazzi A., Labianca R., Sheldon T.A., and Liberati A. Does specialist do it better? The impact of specialisation on the processes and outcomes of care for cancer patients. Ann. Oncol. 9 (1998) 365-374
5. Chen S.S., and Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol. Oncol. 20 (1985) 190-195
6. McGowan L., Lesher L.P., Norris H.J., and Barnett M. Misstaging of ovarian cancer. Obstet. Gynecol. 65 (1985) 568-572
7. Liberati A., Mangioni C., Bratina L., et al. Process and outcome of care for patients with ovarian cancer. Br. Med. J. 291 (1985) 1007-1012
8. Gillis C.R., Hole D.J., Still R.M., Davis J., and Kaye S.B. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 337 (1991) 611-612
9. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 47 (1992) 203-209
10. Mayer A.R., Chambers S.K., Graves E., et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol. Oncol. 47 (1992) 223-227
11. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 71 (1993) 628-633
12. Nguyen H.N., Averette H.E., Hoskins W., Penalver M., Sevin B.U., and Steren A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 72 (1993) 3663-3670
13. Kehoe S., Powell J., Wilson S., and Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br. J. Cancer 70 (1994) 1014-1017
14. Woodman C., Baghdady A., Collins S., and Clyma J.A. What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer?. Br. J. Obstet. Gynaecol. 104 (1997) 135-139
15. Munoz K.A., Harlan L.C., and Trimble E.L. Patterns of care for women with ovarian cancer in the United States. J. Clin. Oncol. 15 (1997) 3408-3415
16. Puls L.E., Carrasco R., Morrow M.S., and Blackhurst D. Stage I ovarian carcinoma: specialty-related differences in survival and management. South. Med. J. 90 (1997) 1097-1100
17. Wolfe C.D., Tilling K., and Raju K.S. Management and survival of ovarian-cancer patients in South East England. Eur. J. Cancer. 33 (1997) 1835-1840
18. Lin P.S., Gershenson D.M., Bevers M.W., Lucas K.R., Burke T.W., and Silva E.G. The current status of surgical staging of ovarian serous borderline tumors. Cancer 85 (1999) 905-911
19. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106 (1999) 1130-1136
20. Stockton D., and Davies T. Multiple cancer site comparison of adjusted survival by hospital of treatment: an East Anglian study. Br. J. Cancer. 82 (2000) 208-212
21. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., and Murdoch J. The surgical management of women with ovarian cancer in South West of England. Br. J. Cancer. 85 (2001) 1824-1830
22. Carney M.E., Lancaster J.M., Ford C., Tsodikov A., and Wiggins C.L. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol. Oncol. 84 (2002) 36-42
23. Grossi M., Quinn M.A., Thursfield V.J., et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med. J. Aust. 177 (2002) 11-16
24. Kumpulainen S., Grenman S., Kyyronen P., Pukkala W., and Sankila R. Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int. J. Cancer 102 (2002) 541-544
25. Elit L., Bondy S.J., Paszat L., Przybysz R., and Levine M. Outcomes in surgery for ovarian cancer. Gynecol. Oncol. 87 (2002) 260-267
26. Cress R.D., O'Malley C.D., Leiserowitz G.S., and Campleman S.L. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J. Clin. Oncol. 21 (2003) 1530-1535
27. Tingulstad S., Skjeldestad F.E., and Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet. Gynecol. 102 (2003) 499-505
28. Harlan L.C., Clegg L.X., and Trimble E.L. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J. Clin. Oncol. 21 (2003) 3488-3494
29. O'Malley C.D., Cress R.D., Campleman S.L., and Leiserowitz G.S. Survival for Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol. Oncol. 91 (2003) 608-615
30. Ioka A., Tsukuma H., Ajiki W., and Oshima A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 95 (2003) 233-237
31. du Bois A., Rochon J., Lamparter C., and Pfisterer J. Impact of cancer characteristics on outcome in ovarian cancer in Germany. Zentralbl. Gynakol. 127 (2005) 18-30
32. du Bois A., Rochon J., Lamparter C., and Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int. J. Gynecol. Cancer 15 (2005) 183-191
33. Engelen M.J., Kos H.E., Willemse P.H., Aalders J.G., de Vries E.G., Schaapveld M., Otter R., and van der Zee A.G. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
34. Kumpulainen S., Kuoppala T., Leminen A., Penttinen J., Puistola U., Pukkala E., Sankila R., Makinen J., and Grenman S. Surgical treatment of ovarian cancer in different hospital categories - a prospective nation-wide study in Finland. Eur. J. Cancer 42 (2006) 388-395
35. Schrag D., Earle C., Xu F., Panageas K.S., Yabroff K.R., Bristow R.E., Trimble E.L., and Warren J.L. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J. Natl. Cancer Inst. 98 (2006) 163-171
36. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., Trimble E.L., Bodurka D.C., Bristow R.E., Carney M., and Warren J.L. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006) 172-180
37. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 11-17
38. Elit L., Chartier C., Oza A., Hirte H., Levine M., and Paszat L. Outcomes for systemic therapy in women with ovarian cancer. Gynecol. Oncol. 103 (2006) 554-558
39. Shylasree T.S., Howells R.E., Lim K., Jones P.W., Fiander A., Adams M., and Evans A.S. Survival in ovarian cancer in Wales: prior to introduction of all Wales guidelines. Int. J. Gynecol. Cancer 16 (2006) 1770-1776
40. Skirnisdottir I., and Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int. J. Oncol. 30 (2007) 727-734
41. Goff B.A., Matthews B.J., Larson E.H., Andrilla C.H., Wynn M., Lishner D.M., and Baldwin L.M. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109 (2007) 2031-2042
42. Chan J.K., Kapp D.S., Shin J.Y., Husain A., Teng N.N., Berek J.S., Osann K., Leiserowitz G.S., Cress R.D., and O'Malley C. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet. Gynecol. 109 (2007) 1342-1350
43. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol. Oncol. 38 (1990) 203-209
44. Grant P.T., Beischer N.A., and Planner R.S. The treatment of gynaecological malignancy in a general public hospital. Med. J. Aust. 157 (1992) 378-380
45. Hole D.J., and Gillis C.R. Use of cancer registry data to evaluate the treatment of ovarian cancer on a hospital basis. Hlth. Rep. 5 (1993) 117-119
46. Junor E.J., Hole D.J., and Gillis C.R. Management of ovarian cancer: referral to a multidisciplinary team matters. Br. J. Cancer 70 (1994) 363-370
47. Tingulstad S., Skjeldestad F.E., Halvorsen T.B., and Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet. Gynecol. 101 (2003) 885-891
48. du Bois A., Pfisterer J., and Kellermann L. Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Ergebnisse einer Umfrage der Organkommission OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Krebsgesellschaft. Gynäkologe 34 (2001) 1029-1040
49. du Bois A., Pfisterer J., Kellermann L., and Kreienberg R. Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: welchen Einfluss hat die Teilnahme an klinischen Studien?. Geburtshilfe Frauenheilkd 61 (2001) 863-871
50. Obermair A., Sevelda P., Oberaigner W., and Marth C. Wie gut ist die Behandlung des Ovarialkarzinoms in Österreich?. Frauenarzt 44 (2003) 732-736
51. Bailey J., Murdoch J., Anderson R., Weeks J., and Foy C. Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 25-29
52. Oberaigner W., and Stuhlinger W. Influence of department volume on cancer survival for gynaecological cancers - a population-based study in Tyrol, Austria. Gynecol. Oncol. 103 (2006) 527-534
53. NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference: ovarian cancer. Screening, treatment, and follow-up. JAMA 273 (1995) 491-497
54. Berek J.S., Bertelsen K., du Bois A., et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10 (1999) S87-S92
55. du Bois A., Quinn M., Thigpen T., et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16 Suppl. 8 (2005) viii7-viii12
56. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J. Natl. Cancer Inst. 95 (2003) 113-125
57. Zanetta G., Rota S., Chiari S., et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. Ann. Oncol. 9 (1998) 1097-1101
58. Le T., Adolph A., Krepart G.V., Lotocki R., and Heywood M.S. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol. Oncol. 85 (2002) 351-355
59. Trimbos J.B., Schueler J.A., van Lent M., Hermans J., and Fleuren G.J. Reasons for incomplete surgical staging in early ovarian carcinoma. Gynecol. Oncol. 37 (1990) 374-377
60. Petignat P., Vajda D., Joris F., and Obrist R. Surgical management of epithelial ovarian cancer at community hospitals: a population-based study. J. Surg. Oncol. 75 (2000) 19-23
61. Sengupta P.S., Jayson G.C., Slade R.J., Eardley A., and Redford J.A. An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br. J. Cancer 80 (1999) 444-447
62. Stier E.A., Barakat R.R., Curtin J.P., Brown C.L., Jones W.B., and Hoskins W.J. Laparotomy to complete staging of presumed early ovarian cancer. Obstet. Gynecol. 87 (1996) 737-740
63. Young R.C., Decker D.G., Taylor Wharton J., et al. Staging laparotomy in early ovarian cancer. JAMA 250 (1983) 3072-3076
64. Winter III W.E., Maxwell G.L., Tian C., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage III epithelial ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 25 (2007) 3621-3627
65. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
66. Griffiths C.T., Parker L.M., Lee S., and Finkler N.J. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int. J. Gynecol. Cancer 12 (2002) 323-331
67. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-980
68. Fader A.N., and Rose P.G. Role of surgery in ovarian carcinoma. J. Clin. Oncol. 25 (2007) 2873-2883
69. Heintz A.P.M., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., and Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67 (1986) 783-788
70. Pfleiderer A. Tumour reduction and chemotherapy in ovarian cancer. Bailliere's Clin. Obstet. Gynaecol. 3 (1989) 119-128
71. Noumoff J., Morgan M., King S., Giuntoli R., and Mikuta J. The specialty of gynecologic oncology as perceived by the public. Gynecol. Oncol. 47 (1992) 48-52
72. Gerhsenson D.M. Why American women are not receiving state-of-the-art gynecologic cancer care. Cancer J. 7 (2001) 450-457
73. Andersen E.S., Knudsen A., Svarrer T., et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol. Oncol. 99 (2005) 552-556
74. Crawford S.C., De Caestecker L., Gillis C.R., et al. Staging quality is related to the survival of women with endometrial cancer: a Scottish population based study. Deficient surgical staging and omission of adjuvant radiotherapy is associated with poorer survival of women diagnosed with endometrial cancer in Scotland during 1996 and 1997. Br. J. Cancer 86 (2002) 837-842
75. Eltabbakh G.H. Effect of surgeon's experience on the surgical outcome of laparoscopic surgery for women with endometrial cancer. Gynecol. Oncol. 78 (2000) 58-61
76. Trimbos J.B., Hellebrekers B.W.J., Kenter G.G., Peters L.A.W., and Zwinderman K.H. The long learning curve of gynaecological cancer surgery: an argument for centralisation. Br. J. Obstet. Gynaecol. 107 (2000) 19-23
77. Begg C.B., Cramer L.D., Hoskins W.J., and Brennan M.F. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280 (1998) 1747-1751
78. Roohan P.J., Bickell N.A., Baptiste M.S., et al. Hospital volume differences and five-year survival from breast cancer. Am. J. Public Health 88 (1998) 454-457
79. Sainsbury R., Howard B., Rider L., Johnston C., and Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 345 (1995) 1265-1270
80. Sosa J.A., Bowman H.M., Gordon T.A., et al. Importance or hospital volume in the overall management of pancreatic cancer. Ann. Surg. 228 (1998) 429-438
81. Schrag D., Cramer L.D., Bach P.B., et al. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 284 (2000) 3028-3035
82. Bach P.B., Cramer L.D., Schrag D., et al. The influence of hospital volume on survival after resection for lung cancer. N. Engl. J. Med. 345 (2001) 181-188
83. Birkemeyer J.D., Siewers A.E., Finlayson E.V.A., et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med. 346 (2002) 1128-1137
84. Peppercorn J.M., Weeks J.C., Cook E.F., et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363 (2004) 263-270
85. Luft H.S., Hunt S.S., and Maerki S.C. The volume-outcome relationship: practice-makes-perfect or selective-referral patterns?. Health Serv. Res. 22 (1987) 157-182
86. Panageas K.S., Schrag D., Riedel E., Bach P.B., and Begg C.B. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann. Intern. Med. 139 (2003) 658-665
87. Giede K.C., Kieser K., Dodge J., and Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol. Oncol. 99 (2005) 447-461
88. Vernooij F., Heintz P., Witteveen E., and van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105 (2007) 801-812